Shares of Evotec AG (NASDAQ:EVO - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $4.16, but opened at $4.32. Evotec shares last traded at $4.25, with a volume of 5,638 shares changing hands.
Analyst Upgrades and Downgrades
EVO has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft raised Evotec from a "sell" rating to a "hold" rating in a research note on Thursday, April 24th. Royal Bank Of Canada restated an "outperform" rating on shares of Evotec in a research note on Thursday, May 15th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Evotec currently has an average rating of "Hold" and an average target price of $5.93.
Read Our Latest Research Report on EVO
Evotec Trading Down 3.3%
The stock's 50 day moving average price is $4.14 and its two-hundred day moving average price is $4.05. The company has a quick ratio of 1.93, a current ratio of 2.03 and a debt-to-equity ratio of 0.46.
Institutional Trading of Evotec
Hedge funds and other institutional investors have recently bought and sold shares of the stock. DCF Advisers LLC lifted its position in shares of Evotec by 5.9% during the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock valued at $956,000 after buying an additional 12,816 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Evotec in the fourth quarter valued at approximately $27,000. Bank of America Corp DE boosted its stake in shares of Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after acquiring an additional 9,289 shares during the last quarter. Lighthouse Investment Partners LLC purchased a new stake in shares of Evotec during the fourth quarter worth approximately $166,000. Finally, CSS LLC IL acquired a new stake in Evotec in the 4th quarter valued at about $50,000. 5.81% of the stock is owned by institutional investors and hedge funds.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
See Also
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
